UK life science research tool specialist Abcam (AIM: ABC) has entered into a definitive agreement to acquire US biotech company AxioMx.
Abcam will acquire AxioMx on a cash-free/debt-free basis for $20 million upfront with further performance-based payments totalling $25 million, which will be made over five years and are based on successful completion of commercial and technical milestones.
The acquisition is expected to close by the end of the month.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze